RTX, MTX, and IVIG (for patients with non-HSAT) [46] | |
• RTX: 375 mg/m2/dose for 4 weeks, followed by maintenance dosage every 4 to 12 weeks. | |
• MTX 0.5 mg/kg weekly enterally, added after 7 weeks; IVIG 500 mg/kg every 4 weeks until antibodies are eliminated. | |
• Bortezomib: 1.3 mg/m2 IV, twice weekly (day 1, 4, 8 and 11, equivalent to 1 cycle) (total 3–6 cycles). | |
• RTX 375 mg/m2 IV (on initial round of weekly RTX infusion, thereafter RTX infusions every 4 to 12 weeks, to a maximum of 52 doses). | |
• MTX 15 mg/m2 os; IVIG 400–500 mg/kg iv. | |
RTX, bortezomib, sirolimus, and IVIG [48] | |
• RTX 375 mg/m2, 3 weekly infusions. | |
• Bortezomib 1.3 mg/m2, 6 twice-weekly doses. | |
• IVIG monthly, first dose 1.0 g/kg, subsequent doses of 0.5 g/kg. | |
• Sirolimus started at week 4 (10–20 kg: 1.0–1.5 mg/day; 20–30 kg: 1.5–2 mg/day; double dose on first day; dose adjusted on the basis of serum levels (reference range 4–12 μg/l). |